ONCOLOGY

Latest PHE hepatitis C report for England and the UK.

Since the first case in October, the team has successfully treated three more patients.

The variant occurs in 81% with hemochromatosis.

Routine HCC surveillance should be done on individuals with virologically cured HCV.

Cabozantinib and mTOR inhibitors may represent a novel therapeutic approach for hepatocellular carcinoma.

The options differ on the basis of stage and timing.

The choice should be based on cost, tolerability rather than efficacy in HCC prevention.

Phase 3 data are insufficient to guide later lines of treatment.

Findings emphasise the importance of promoting physical activity.

Expansion would include tumors that do not meet Milan criteria but respond to locoregional therapies.

Patients with high very early recurrence risk might benefit from supplementary therapy.

Royal Marsden study finds that microscopic colitis is an important subgroup in patients with immune checkpoint inhibitor-related diarrhoea/colitis.

Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation.

A predictive role for IL-27 was demonstrated in 2 large prospective cohort studies.